The use of frozen section and immunohistochemistry for sentinel lymph node biopsy in breast cancer

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Intraoperative pathologic evaluation of the sentinel lymph node (SLN) may guide immediate (synchronous) completion axillary lymph node dissection (ALND) for up to two-thirds of patients with nodal disease for breast cancer. The false-negative rates average one-third of cases, and one must be aware of false-positive results as this would result in unnecessary and morbid completion ALND. Currently, the use of immunohistochemistry (IHC) is controversial. There is no question that cytokeratin staining improves the sensitivity; however, there is no evidence that any of these "positive" cells are clinically significant and warrant therapy. Prospective randomized trials will be necessary to confirm or debunk the hypothesis that "sub- micrometastatic" disease has clinical significance.

Original languageEnglish (US)
Pages (from-to)414-419
Number of pages6
JournalAmerican Surgeon
Volume70
Issue number5
StatePublished - 2004

Fingerprint

Sentinel Lymph Node Biopsy
Frozen Sections
Lymph Node Excision
Immunohistochemistry
Breast Neoplasms
Keratins
Staining and Labeling
Therapeutics
Sentinel Lymph Node

ASJC Scopus subject areas

  • Surgery

Cite this

The use of frozen section and immunohistochemistry for sentinel lymph node biopsy in breast cancer. / Chao, Celia.

In: American Surgeon, Vol. 70, No. 5, 2004, p. 414-419.

Research output: Contribution to journalArticle

@article{4a189139c57a45f59fc0234937b8fb2f,
title = "The use of frozen section and immunohistochemistry for sentinel lymph node biopsy in breast cancer",
abstract = "Intraoperative pathologic evaluation of the sentinel lymph node (SLN) may guide immediate (synchronous) completion axillary lymph node dissection (ALND) for up to two-thirds of patients with nodal disease for breast cancer. The false-negative rates average one-third of cases, and one must be aware of false-positive results as this would result in unnecessary and morbid completion ALND. Currently, the use of immunohistochemistry (IHC) is controversial. There is no question that cytokeratin staining improves the sensitivity; however, there is no evidence that any of these {"}positive{"} cells are clinically significant and warrant therapy. Prospective randomized trials will be necessary to confirm or debunk the hypothesis that {"}sub- micrometastatic{"} disease has clinical significance.",
author = "Celia Chao",
year = "2004",
language = "English (US)",
volume = "70",
pages = "414--419",
journal = "The American surgeon",
issn = "0003-1348",
publisher = "Southeastern Surgical Congress",
number = "5",

}

TY - JOUR

T1 - The use of frozen section and immunohistochemistry for sentinel lymph node biopsy in breast cancer

AU - Chao, Celia

PY - 2004

Y1 - 2004

N2 - Intraoperative pathologic evaluation of the sentinel lymph node (SLN) may guide immediate (synchronous) completion axillary lymph node dissection (ALND) for up to two-thirds of patients with nodal disease for breast cancer. The false-negative rates average one-third of cases, and one must be aware of false-positive results as this would result in unnecessary and morbid completion ALND. Currently, the use of immunohistochemistry (IHC) is controversial. There is no question that cytokeratin staining improves the sensitivity; however, there is no evidence that any of these "positive" cells are clinically significant and warrant therapy. Prospective randomized trials will be necessary to confirm or debunk the hypothesis that "sub- micrometastatic" disease has clinical significance.

AB - Intraoperative pathologic evaluation of the sentinel lymph node (SLN) may guide immediate (synchronous) completion axillary lymph node dissection (ALND) for up to two-thirds of patients with nodal disease for breast cancer. The false-negative rates average one-third of cases, and one must be aware of false-positive results as this would result in unnecessary and morbid completion ALND. Currently, the use of immunohistochemistry (IHC) is controversial. There is no question that cytokeratin staining improves the sensitivity; however, there is no evidence that any of these "positive" cells are clinically significant and warrant therapy. Prospective randomized trials will be necessary to confirm or debunk the hypothesis that "sub- micrometastatic" disease has clinical significance.

UR - http://www.scopus.com/inward/record.url?scp=2542528463&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2542528463&partnerID=8YFLogxK

M3 - Article

C2 - 15156949

AN - SCOPUS:2542528463

VL - 70

SP - 414

EP - 419

JO - The American surgeon

JF - The American surgeon

SN - 0003-1348

IS - 5

ER -